Appearance:Solid powder
Purity: > 98%
Cat No: | I002553 |
Cas No: | 202189-78-4 |
Product-Name: | Bilastine |
IUPAC Name: | 2-[4-[2-[4-[1-(2-ethoxyethyl)benzimidazol-2-yl]piperidin-1-yl]ethyl]phenyl]-2-methylpropanoic acid |
InChI: | InChI=1S/C28H37N3O3/c1-4-34-20-19-31-25-8-6-5-7-24(25)29-26(31)22-14-17-30(18-15-22)16-13-21-9-11-23(12-10-21)28(2,3)27(32)33/h5-12,22H,4,13-20H2,1-3H3,(H,32,33) |
InChIKey: | ACCMWZWAEFYUGZ-UHFFFAOYSA-N |
SMILES: | CCOCCN1C2=CC=CC=C2N=C1C3CCN(CC3)CCC4=CC=C(C=C4)C(C)(C)C(=O)O |
Bilastine(CAS 202189-78-4) is a selective histamine H1 receptor antagonist used for treatment of allergic rhinoconjunctivitis and urticaria.It exerts its effect as a selective histamine H1 receptor antagonist, and has a potency similar to cetirizine and is superior to fexofenadine. It was developed in Spain by FAES Farma. Bilastine is approved in the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria, but it is not approved by the U.S. Food and Drug Administration for any use in the United States. Bilastine has been effective in the treatment of ocular symptoms and diseases of allergies, including rhinoconjuctivitis. Additionally, bilastine has been shown to improve quality of life, and all nasal and ocular symptoms related to allergic rhinitis.
Bilastine is a histamine H1 receptor antagonist. Faes Farma completed a phase III trial in Allergic conjunctivitis in Hungary, Lithuania, Poland and Slovakia(Ophthalmic) (EudraCT2018-002248-95) in 2020.
1: Sádaba Díaz de Rada B, Azanza Perea JR, Gomez-Guiu Hormigos A. Bilastine for the relief of allergy symptoms. Drugs Today (Barc). 2011 Apr;47(4):251-62. doi: 10.1358/dot.2011.47.4.1587029. Review. PubMed PMID: 21573249.
2: Dávila I, Sastre J, Mullol J, Montoro J, Jáuregui I, Ferrer M, del Cuvillo A, Bartra J, Valero A. Effect of bilastine upon nasal obstruction. J Investig Allergol Clin Immunol. 2011;21 Suppl 3:2-8. Review. PubMed PMID: 22185044.
3: Corcóstegui R, Labeaga L, Innerárity A, Berisa A, Orjales A. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs R D. 2006;7(4):219-31. PubMed PMID: 16784247.
4: Corcóstegui R, Labeaga L, Innerárity A, Berisa A, Orjales A. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D. 2005;6(6):371-84. PubMed PMID: 16274260.
Your information is safe with us.